Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.2249
https://www.valueinhealthjournal.com/article/S1098-3015(13)04161-2/fulltext
Title :
Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)04161-2&doi=10.1016/j.jval.2013.08.2249
First page :
A721
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2061